32 studies found for:    AKT1
Show Display Options
Rank Status Study
1 Recruiting Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null
Conditions: Cancer;   Solid Tumors
Intervention: Drug: ARQ 751
2 Recruiting Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Conditions: Advanced Solid Malignancy;   Safety and Tolerability;   Pharmacokinetics;   Pharmacodynamics;   Tumour Response;   Advanced or Metastatic Breast Cancer;   Ovarian Cancer;   Cervical Cancer;   Endometrial Cancer;   PIK3CA;   AKT1;   PTEN;   ER+;   HER2+
Intervention: Drug: AZD5363
3 Active, not recruiting Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Condition: Neoplasms
Intervention: Drug: BAY1125976
4 Enrolling by invitation A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
Condition: Schizophrenia
Intervention:
5 Recruiting NGS Genome Analysis in Personalisation of Lung Cancer Treatment
Condition: Lung Cancer
Intervention: Other: blood sample, biopsy
6 Active, not recruiting Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Conditions: Solid Tumor;   Malignant Lymphoma;   Tumor
Intervention: Drug: ARQ 092
7 Recruiting Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole
Conditions: Solid Tumors;   Ovarian Cancer;   Endometrial Cancer
Interventions: Drug: ARQ 092 + carboplatin + paclitaxel;   Drug: ARQ 092 + paclitaxel;   Drug: ARQ 092 + anastrozole
8 Recruiting Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome
Condition: Proteus Syndrome
Intervention: Drug: ARQ 092
9 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
10 Recruiting Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia
Condition: Tumor Induced Oncogenic Osteomalacia
Intervention:
11 Recruiting Molecular Phenotype Changes and Personalized Treatment for CRPC
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel & Prednisone;   Drug: DP & Targeted drugs;   Drug: cisplatin & Etoposide;   Drug: EP & Targeted drugs
12 Recruiting Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment
Condition: Malignant Solid Neoplasms
Interventions: Drug: Nilotinib (400 mg BID);   Drug: Everolimus (10 mg QD);   Drug: Sorafenib (400 mg BID);   Drug: Lapatinib (1500 mg QD);   Drug: Pazopanib (800 mg QD)
13 Active, not recruiting Trametinib With GSK2141795 in BRAF Wild-type Melanoma
Condition: Melanoma
Interventions: Drug: Trametinib (GSK1120212);   Drug: GSK2141795
14 Enrolling by invitation Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism
Conditions: Aging;   Sleep Restriction;   Circadian Disruption
Interventions: Behavioral: Circadian Disruption;   Behavioral: Sleep Restriction;   Behavioral: Control
15 Completed A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)
Condition: Advanced Cancer
Interventions: Drug: Comparator: MK-8033;   Drug: Comparator: MK-8033 +/- omeprazole
16 Completed Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Condition: Malignant Neoplasm
Interventions: Drug: Cixutumumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Temsirolimus
17 Recruiting Diet and Exercise Program in Promoting Weight Loss and Improving Health in Patients With Low- or Low-Intermediate-Risk Prostate Cancer
Conditions: Obesity;   Overweight;   Prostate Adenocarcinoma;   Stage IIA Prostate Cancer
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Exercise Intervention;   Other: Informational Intervention;   Other: Laboratory Biomarker Analysis;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
18 Recruiting Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus
Condition: SOLID TUMOR
Intervention:
19 Completed Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
Condition: Cardiovascular Abnormalities
Intervention: Drug: Sirolimus
20 Active, not recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Indicates status has not been verified in more than two years